FULC [NASD]
Fulcrum Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.38 Insider Own1.30% Shs Outstand40.64M Perf Week-4.28%
Market Cap199.75M Forward P/E- EPS next Y-2.84 Insider Trans-31.07% Shs Float37.64M Perf Month-28.90%
Income-89.80M PEG- EPS next Q-0.66 Inst Own97.20% Short Float9.93% Perf Quarter-79.20%
Sales17.00M P/S11.75 EPS this Y18.10% Inst Trans6.78% Short Ratio4.10 Perf Half Y-71.14%
Book/sh4.65 P/B1.06 EPS next Y-6.10% ROA-42.30% Target Price28.38 Perf Year-52.14%
Cash/sh4.81 P/C1.02 EPS next 5Y6.40% ROE-48.40% 52W Range3.21 - 33.10 Perf YTD-72.19%
Dividend- P/FCF- EPS past 5Y- ROI-38.30% 52W High-85.13% Beta-
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low53.27% ATR0.64
Employees104 Current Ratio10.90 Sales Q/Q-45.80% Oper. Margin- RSI (14)35.21 Volatility7.87% 15.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.20% Profit Margin- Rel Volume0.43 Prev Close4.90
ShortableYes LT Debt/Eq0.00 EarningsMay 09 BMO Payout- Avg Volume912.16K Price4.92
Recom1.70 SMA20-13.53% SMA50-35.24% SMA200-68.18% Volume392,205 Change0.41%
Mar-08-22Initiated Oppenheimer Outperform $33
Mar-03-22Upgrade BofA Securities Underperform → Neutral
Aug-11-21Upgrade Morgan Stanley Equal-Weight → Overweight $12 → $34
Apr-26-21Resumed Credit Suisse Outperform $26
Mar-22-21Initiated Credit Suisse Outperform $26
Mar-02-21Initiated Stifel Buy $18
Oct-16-20Initiated Piper Sandler Overweight $22
Aug-12-20Reiterated H.C. Wainwright Buy $28 → $20
Aug-12-20Downgrade Morgan Stanley Overweight → Equal-Weight $11
Aug-12-20Downgrade BofA Securities Neutral → Underperform $11
Jun-19-20Downgrade BofA/Merrill Buy → Neutral $19 → $23
Jun-17-20Initiated BTIG Research Buy $27
Oct-03-19Initiated H.C. Wainwright Buy $21
Aug-12-19Initiated BofA/Merrill Buy $19
Jun-10-22 04:02PM  
08:24AM  
07:02AM  
May-12-22 05:08PM  
May-11-22 12:38PM  
May-10-22 06:21AM  
May-09-22 09:55AM  
08:25AM  
07:00AM  
May-06-22 08:00AM  
May-05-22 06:25PM  
08:00AM  
May-04-22 09:15AM  
May-03-22 09:35AM  
May-02-22 08:00AM  
Apr-28-22 03:02PM  
Apr-13-22 07:33AM  
Apr-08-22 08:00AM  
Apr-04-22 09:35AM  
Apr-01-22 08:36AM  
08:30AM  
Mar-17-22 08:00AM  
Mar-14-22 08:00AM  
Mar-11-22 08:00AM  
Mar-07-22 10:00AM  
Mar-03-22 11:24AM  
08:35AM  
07:01AM  
07:00AM  
Feb-24-22 09:15AM  
08:00AM  
Feb-15-22 06:53PM  
Feb-12-22 07:33AM  
Feb-11-22 08:00AM  
Feb-10-22 08:00AM  
Feb-07-22 05:38PM  
Jan-19-22 09:38PM  
Jan-12-22 02:58PM  
Jan-10-22 07:00AM  
Jan-07-22 08:00AM  
Jan-06-22 08:00AM  
Jan-04-22 08:00AM  
Dec-23-21 12:38PM  
Dec-21-21 06:38PM  
Dec-14-21 05:59AM  
Dec-06-21 07:00AM  
Nov-17-21 08:00AM  
Nov-04-21 08:35AM  
07:00AM  
Nov-03-21 07:00AM  
Oct-28-21 07:00AM  
Oct-14-21 10:05AM  
Oct-01-21 07:00AM  
Sep-21-21 01:59PM  
Sep-20-21 07:00AM  
Sep-10-21 07:00AM  
Sep-08-21 07:00AM  
Sep-02-21 07:00AM  
Aug-23-21 06:47AM  
Aug-16-21 04:01PM  
11:51AM  
06:16AM  
Aug-12-21 01:33AM  
Aug-11-21 10:09PM  
04:06PM  
Aug-10-21 04:24PM  
04:04PM  
10:56AM  
09:05AM  
07:01AM  
07:00AM  
Aug-04-21 07:00AM  
Aug-03-21 03:00PM  
Jul-30-21 11:14AM  
Jul-01-21 01:25AM  
Jun-24-21 07:00AM  
Jun-21-21 07:00AM  
May-12-21 04:19PM  
07:00AM  
02:08AM  
May-07-21 07:00AM  
05:09AM  
May-06-21 08:55AM  
07:01AM  
07:00AM  
06:15AM  
Apr-29-21 07:00AM  
Apr-09-21 01:15PM  
Mar-24-21 09:29AM  
Mar-18-21 11:30AM  
Mar-04-21 08:25AM  
07:01AM  
07:00AM  
06:15AM  
Feb-26-21 07:00AM  
07:00AM  
Feb-19-21 07:00AM  
Feb-17-21 02:47AM  
Jan-22-21 04:00PM  
Jan-19-21 10:34PM  
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gould Robert JDirectorJun 07Option Exercise7.8471,435560,050578,065Jun 08 07:33 PM
Gould Robert JDirectorJun 07Sale8.0971,435577,895506,630Jun 08 07:33 PM
Gould Robert JDirectorJun 06Option Exercise7.8424,382191,155531,012Jun 06 07:00 PM
Gould Robert JDirectorJun 06Sale8.1024,382197,592506,630Jun 06 07:00 PM
Gould Robert JDirectorJun 03Option Exercise7.8425,551200,320532,181Jun 06 07:00 PM
Gould Robert JDirectorJun 03Sale7.9525,551203,056506,630Jun 06 07:00 PM
Gould Robert JDirectorJun 02Option Exercise7.8416,689130,842523,319Jun 06 07:00 PM
Gould Robert JDirectorJun 02Sale7.9216,689132,162506,630Jun 06 07:00 PM
Gould Robert JDirectorApr 07Option Exercise7.845,63144,147512,261Apr 11 05:00 PM
Gould Robert JDirectorApr 07Sale24.025,631135,228506,630Apr 11 05:00 PM
Gould Robert JDirectorApr 05Option Exercise7.8452,552412,008559,182Apr 05 07:00 PM
Gould Robert JDirectorApr 05Sale24.2652,5521,274,775506,630Apr 05 07:00 PM
Gould Robert JDirectorApr 04Option Exercise7.847,23556,722513,865Apr 05 07:00 PM
Gould Robert JDirectorApr 04Sale24.027,235173,749506,630Apr 05 07:00 PM
Gould Robert JDirectorApr 01Option Exercise7.8434,464270,198541,094Apr 05 07:00 PM
Gould Robert JDirectorApr 01Sale24.0334,464828,160506,630Apr 05 07:00 PM
Stuart BryanSee RemarksAug 11Option Exercise7.8428,000219,52028,000Aug 12 04:20 PM
Stuart BryanSee RemarksAug 11Sale23.7528,000665,0000Aug 12 04:20 PM
Stuart BryanSee RemarksAug 10Option Exercise7.8432,000250,88032,000Aug 12 04:20 PM
Moxham ChristopherChief Scientific OfficerAug 10Option Exercise7.8451,785405,99431,071Aug 12 04:20 PM
Stuart BryanSee RemarksAug 10Sale17.5032,000560,0000Aug 12 04:20 PM
Moxham ChristopherChief Scientific OfficerAug 10Sale17.6051,785911,4160Aug 12 04:20 PM